- Conditions
- Alzheimer's Disease
- Interventions
- icosapent ethyl (IPE), gel cap placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes, Coronary Artery Disease
- Interventions
- Icosapent ethyl
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Nutrition, Healthy
- Interventions
- DHA/EPA fortified chicken plus Placebo, non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement, non-DHA bio-enhanced chicken plus supplement DHA Omega-3, 25(OH)D bioenhanced chicken and eggs plus placebo, Dietary Supplement: DHA/EPA fortified eggs plus Placebo, non-DHA bio-enhanced eggs plus supplement DHA Omega-3, non-25(OH)D fortified chicken/eggs plus placebo
- Dietary Supplement · Other
- Lead sponsor
- Cornell University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Ithaca, New York
- Conditions
- Major Depressive Disorder, Overweight, Inflammation
- Interventions
- Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
- Other · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Boston, Massachusetts
- Conditions
- Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
- Interventions
- Fish Oil, Flaxseed Oil, Placebo
- Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hypertriglyceridemia
- Interventions
- rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 80
- States / cities
- Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
- Conditions
- Hypertriglyceridemia
- Interventions
- DHA-enriched, EPA-enriched
- Dietary Supplement
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
- Interventions
- Eicosapentaenoic acid (omega-3 fatty acid), Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertriglyceridemia
- Interventions
- Omega-3-acid ethyl esters, Placebo
- Drug
- Lead sponsor
- Babu Balagopal
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Colon Cancer
- Interventions
- AMR101 (VASCEPA, icosapent ethyl)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 18
- States / cities
- Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
- Conditions
- Hypertriglyceridemia
- Interventions
- Simvastatin, acetylsalicylic acid (ASA), omefas
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Chronic Obstructive Pulmonary Disease, Muscle Wasting
- Interventions
- Olive oil, Fish oil, Fish oil and placebo
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Treatment Resistant Depression, Inflammation, Overweight
- Interventions
- Omega 3, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
- Conditions
- Elevated Triglycerides, Cardiovascular Risk Factor
- Interventions
- DPA enriched n-3, n-3 control, Placebo
- Dietary Supplement
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Healthy
- Interventions
- Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
- Drug · Dietary Supplement
- Lead sponsor
- Carsten Skarke, MD
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Asthma
- Interventions
- EPA enriched fish oils
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Mather, California
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Age-related Memory Disorders, Mood Disorders
- Interventions
- Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder
- Dietary Supplement · Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 62 Years to 80 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hypertriglyceridemia
- Interventions
- 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania